Table 1.
Baseline Clinical Characteristics of the Study Population in the Discovery Set and Validation Set
| Group | Discovery Set | Validation Set | ||||
|---|---|---|---|---|---|---|
| Overall survival | OS < 6M | OS > 6M | *p | OS < 6M | OS > 6M | *p |
| Number of patients | 27 | 19 | 17 | 17 | ||
| Sex | ||||||
| Men | 15 (55.5%) | 10 (52.6%) | 9 (52.9%) | 9 (52.9%) | ||
| Women | 12 (44.5%) | 9 (47.4%) | 0.844 | 8 (47.1%) | 8 (47.1%) | 1 |
| Age, yr | 58.5 [55.3, 60.8] | 64.0 [56.3, 75.0] | 0.744 | 62.5 [58.6, 67.2] | 63.7 [58.5, 71.3] | 0.911 |
| BMI (kg/m2) | 24.7 [19.8, 28.0] | 21.8 [20.7, 23.4] | 0.895 | 23.5 [20.5, 27.4] | 22.4 [20.1, 25.3] | 0.864 |
| Histology | ||||||
| Adenocarcinomas | 15 (55.5%) | 11 (57.8%) | 10 (58.8%) | 10 (58.8%) | ||
| Squamous cell carcinomas | 12 (44.5%) | 8 (42.2%) | 0.874 | 7 (41.2%) | 7 (41.2%) | 1 |
| Number of treatment lines before start of nivolumab | ||||||
| 1 | 2 (7.4%) | 0 | 3 (17.6%) | 2 (11.7%) | ||
| 2 | 12 (44.5%) | 12 (63.1%) | 9 (52.9%) | 7 (41.1%) | ||
| 3 | 8 (29.6%) | 7 (36.8%) | 5 (29.4%) | 6 (35.2%) | ||
| 4 | 5 (18.5%) | 0 | 0.501 | 0 | 2 (11.7%) | 0.504 |
| ECOG status | ||||||
| 0 | 0 | 5 (26.3%) | 3 (17.6%) | 1 (5.8%) | ||
| 1 | 14 (51.8%) | 9 (47.3%) | 8 (47%) | 9 (52.9%) | ||
| 2 | 12 (44.5%) | 3 (15.7%) | 6 (35.2%) | 7 (41.1%) | ||
| 3 | 1 (3.7%) | 2 (10.5%) | 0.044 | 0 | 0 | 0.768 |
| Smoking status (%) | ||||||
| Never smoker | 5 (18.5) | 2 (10.5) | 3 (17.7) | 3 (17.7) | ||
| Ever smoker | 22 (81.5) | 17 (89.5) | 0.884 | 14 (82.3) | 14 (82.3) | 1 |
Notes: The response groups are divided into overall survival >6 months (6m) and < 6 months (6m). *Chi-square test. Sex, histology, and number of treatment lines before start of nivolumab and ECOG status are shown for the different groups.
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group.